Co-stimulation of CD40 also increased restored TLR9 induced proliferation of SLE B cells. As already reported, 93 the induction of CD27+CD38+ PB/PC was lower compared to TLR9 or TLR9/BCR stimulation.

The drug of interest, frexalimab, is a second-generation anti-CD40L IgG1 monoclonal antibody. Frexalimab has been Fc-engineered, allowing it to evade platelet aggregation normally triggered by ...

The CD40–CD40L costimulatory pathway regulates adaptive and innate immune responses and has been implicated in the pathogenesis of multiple sclerosis. Frexalimab is a second-generation anti ...

Frexalimab, a novel, second-generation anti-CD40L antibody, shows "strikingly positive" effects in the treatment of relapsing multiple sclerosis (MS), significantly reducing disease activity.

New data, being presented in a late-breaking session at the 2023 Consortium of Multiple Sclerosis Centers annual meeting, demonstrate that frexalimab, Sanofi’s novel second-generation investigational ...

Medigene AG, an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumours, reports it has partnered with Helmholtz Munich to acquire the ...

Medigene AG reports it has partnered with Helmholtz Munich to acquire the exclusive, worldwide rights to the CD40L-CD28 costimulatory switch receptor adding to the portfolio of technologies within ...

In antigen‐activated B cells, CD40L stimulation triggers proliferation, germinal center formation, antibody affinity maturation, and class‐switching and long‐term memory responses (Van Kooten & ...

In monocytes, macrophages, and dendritic cells, CD40L stimulation enhances survival and killing and activates production of cytokines such as IL‐1, IL‐12, and TNF‐α (Van Kooten & Banchereau, 2000).

Platelet CD40L also contributes to neuroinflammation by inducing activation of astrocytes and microglia (90). Furthermore, activated platelets express soluble CD40L (sCD40L) which in turn induces ...

They show that GC and T FH are required to bias towards CD80 + B mem and that there is a relationship between the amount of CD40L stimulation and proportional representation of the B mem subsets.

To test the involvement of CD40, we used 5C8, which is an anti CD40L/CD40 antagonist. 34 Interestingly, NF‐κB activation was abolished entirely by 5C8 following CD40L stimulation, which demonstrates ...